Udenafil

Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research[1][2].

Product Specifications

CAS Number

[268203-93-6]

Product Name Alternative

DA8159

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Udenafil.html

Purity

99.67

Solubility

DMSO : ≥ 33 mg/mL

Smiles

O=S(C1=CC=C(OCCC)C(C2=NC3=C(N(C)N=C3CCC)C(N2)=O)=C1)(NCCC4N(C)CCC4)=O

Molecular Formula

C25H36N6O4S

Molecular Weight

516.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhao, C., et al., Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2011. 107 (12) : p. 1943-7.|[2]Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5 (4) : p. 946-53.